ATE294594T1 - Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung - Google Patents

Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung

Info

Publication number
ATE294594T1
ATE294594T1 AT99912502T AT99912502T ATE294594T1 AT E294594 T1 ATE294594 T1 AT E294594T1 AT 99912502 T AT99912502 T AT 99912502T AT 99912502 T AT99912502 T AT 99912502T AT E294594 T1 ATE294594 T1 AT E294594T1
Authority
AT
Austria
Prior art keywords
polynucleotide
composition
polynucleotide composition
lyophilized
cryoprotectant
Prior art date
Application number
AT99912502T
Other languages
English (en)
Inventor
Shankar Musunuri
Patrick P Deluca
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE294594T1 publication Critical patent/ATE294594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99912502T 1998-03-13 1999-03-12 Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung ATE294594T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7808098P 1998-03-13 1998-03-13
PCT/US1999/005547 WO1999045966A1 (en) 1998-03-13 1999-03-12 Polynucleotide composition, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
ATE294594T1 true ATE294594T1 (de) 2005-05-15

Family

ID=22141799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912502T ATE294594T1 (de) 1998-03-13 1999-03-12 Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung

Country Status (14)

Country Link
US (1) US20080081366A1 (de)
EP (1) EP1061955B1 (de)
JP (1) JP2002506048A (de)
KR (1) KR100625385B1 (de)
CN (1) CN100471522C (de)
AT (1) ATE294594T1 (de)
AU (1) AU765177B2 (de)
BR (1) BR9908754A (de)
CA (1) CA2322232A1 (de)
DE (1) DE69925113T2 (de)
ES (1) ES2239440T3 (de)
IL (1) IL138306A0 (de)
PT (1) PT1061955E (de)
WO (1) WO1999045966A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600464B1 (ko) * 1998-05-22 2006-07-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 안정한 유전자 제제
JP4538150B2 (ja) * 1998-08-14 2010-09-08 ヴァレンティス，インコーポレイテッド 核酸分子の保護された単一バイアル調製物、インライン混合によってそれを形成する方法、及び関連する生成物及び方法
CA2389613A1 (en) * 1999-11-19 2001-05-25 Zycos Inc. Continuous-flow method for preparing microparticles
JP2001316297A (ja) * 2000-02-23 2001-11-13 Kaken Pharmaceut Co Ltd 遺伝子包埋リポソーム製剤及びその製法
TR201910060T4 (tr) 2001-12-20 2019-07-22 Merck Sharp & Dohme SYN3 bileşimleri ve yöntemleri.
MXPA04008890A (es) 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
AU2003218168A1 (en) * 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
CA2508279A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
EP1581201A4 (de) 2002-12-23 2011-03-30 Vical Inc Verfahren zur herstellung steriler arzneimittel auf polynukleotidbasis
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
WO2008051245A2 (en) * 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
KR100777249B1 (ko) 2006-02-14 2007-11-28 (주)바이오니아 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
DE102006038240A1 (de) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Verfahren zur Herstellung eines Komposits aus Oligo- oder Polynucleotiden und hydrophoben biodegradierbaren Polymeren sowie nach dem Verfahren erhaltenes Komposit
GB0701253D0 (en) * 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
EP1970441A1 (de) * 2007-03-06 2008-09-17 BioAlliance Pharma Plasmid mit einer Sequenz, die eine Disintegrin-Domäne von Metargidin (RDD) kodiert
KR101290322B1 (ko) * 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제
DK3336082T3 (da) 2011-06-08 2020-04-27 Translate Bio Inc Spaltelige lipider
CN104854128A (zh) 2012-07-19 2015-08-19 硕腾有限责任公司 牛流感病毒组合物
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
SG11201705312PA (en) * 2014-12-29 2017-07-28 Bonac Corp Composition containing nucleic acid molecule stably
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
BR112018002919B1 (pt) 2015-08-14 2024-02-27 Zoetis Services Llc Composição imunogênica eficaz compreendendo uma cepa de mycoplasma bovis e usos da mesma para prevenção de doenças causadas por mycoplasma bovis
PT3534922T (pt) 2016-11-04 2024-06-07 Takeda Pharmaceuticals Co Formulações de vírus adenoassociado
AU2019299964A1 (en) 2018-07-11 2021-01-21 Takeda Pharmaceutical Company Limited AAV compositions
AU2019305221B2 (en) * 2018-07-19 2024-11-07 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy
CN110596227B (zh) * 2019-08-08 2021-11-23 河北省食品检验研究院（国家果类及农副加工产品质量监督检验中心、河北省食品安全实验室） 飞行时间质谱即用型斯坦利沙门氏菌定性标准样品的制备方法
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
KR102460006B1 (ko) * 2021-11-22 2022-10-27 주식회사 리엔젠 폴리뉴클레오타이드 및 히알루론산 포함하는 피부 필러 조성물의 동결건조 제조방법 및 이에 따라 제조된 폴리뉴클레오타이드 및 히알루론산 포함하는 피부 필러 조성물
CN119372199B (zh) * 2024-11-19 2026-04-21 郑州安图生物工程股份有限公司 干燥保护剂、干燥方法及核酸质控品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (en) * 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
US5709076A (en) * 1992-09-14 1998-01-20 Lawlor; Shawn P. Method and apparatus for power generation using rotating ramjet which compresses inlet air and expands exhaust gas against stationary peripheral wall
JPH08511956A (ja) * 1994-04-07 1996-12-17 アクゾ・ノベル・エヌ・ベー Ｒｎａを含む凍結乾燥組成物
WO1996027393A1 (en) * 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
ES2234018T3 (es) * 1996-04-26 2005-06-16 MERCK & CO., INC. Formulaciones de vacunas de adn.
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren

Also Published As

Publication number Publication date
DE69925113D1 (de) 2005-06-09
EP1061955A1 (de) 2000-12-27
EP1061955B1 (de) 2005-05-04
AU3086899A (en) 1999-09-27
BR9908754A (pt) 2000-11-28
PT1061955E (pt) 2005-08-31
CA2322232A1 (en) 1999-09-16
CN1294520A (zh) 2001-05-09
KR20010074441A (ko) 2001-08-04
IL138306A0 (en) 2001-10-31
CN100471522C (zh) 2009-03-25
WO1999045966A1 (en) 1999-09-16
US20080081366A1 (en) 2008-04-03
JP2002506048A (ja) 2002-02-26
KR100625385B1 (ko) 2006-09-18
ES2239440T3 (es) 2005-09-16
AU765177B2 (en) 2003-09-11
DE69925113T2 (de) 2006-01-19

Similar Documents

Publication Publication Date Title
DE69925113D1 (de) Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
DE69916435D1 (de) Verfahren zur verbesserung der ductilität von nitinol
DE59100581D1 (de) Verfahren zur herstellung von torfersatz, anlage zur durchführung dieses verfahrens, anwendung des verfahrens und nach diesem verfahren hergestellter torfersatz.
DK0695408T3 (da) Fremgangsmåde til forbedring af celluloseholdige produkters modstandsevne over for skimmel og råd
DE60003912D1 (de) Verfahren zur herstellung von konditionierungstüchern
NO981106D0 (no) Fremgangsmåte til fremstilling av varmehemmende materiale, samt anvendelse derav
ATE294152T1 (de) Substituierte tetrahydro-naphtaline und analoge verbindungen
NO20012966D0 (no) Kondenserte 1,2,4-tiadiazinderivater, deres fremstilling og anvendelse
ATE375090T1 (de) Bioaktive peptide, ihre verwendung und verfahren zu ihre herstellung
DE59107488D1 (de) Verfahren zur herstellung wasch- und reinigungsaktiver tensidgranulate
EP1555033A3 (de) Polynukleotidzusammensetzung, Verfahren zu deren Herstellung und Verwendung
MD940401A (ro) Compoziţie pentru decelerarea inflamării şi procedeu de decelerare a inflamării
DE69917669D1 (de) Glutaminsäure und glykolsäure verwendendes verfahren zur erhöhung der pflanzenproduktivität
ATE188201T1 (de) Verfahren zur herstellung von oligomethylenharnstoff
DE69514122D1 (de) Lösungsmittelfreies verfahren zur herstellung von 2,6 difluorbenzonitril
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
DE3854756D1 (de) Verfahren zum Kompostieren von Müll.
ATE195547T1 (de) Antioxidantzusammensetzung und verfahren zu dessen herstellung
ATE286013T1 (de) Verfahren zur herstellung von polyhalogenierten para-trifluoroanilinen
ES2155911T3 (es) Derivados de alcanfor como nuevos odorantes.
ATE288514T1 (de) Verfahren zur behandlung von wolle enthaltenden geweben, insbesondere kleidungsstücken
DK1214315T3 (da) 1,4-Dihydropyridin-5-carboxylsyreesterderivater og fremgangsmåde til fremstilling af samme
ATE105293T1 (de) Phosphortrilactame und verfahren zu deren herstellung.
DE59100200D1 (de) Verfahren zur herstellung von plangenauen ziegelsteinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1061955

Country of ref document: EP

REN Ceased due to non-payment of the annual fee